论文部分内容阅读
目的探讨α糖苷酶抑制剂与二肽基肽酶-4(DPP-4)抑制剂联合治疗T2DM患者的有效性及安全性。方法将120例T2DM患者随机分为观察组和对照组,各60例。观察组采用α糖苷酶抑制剂与DPP-4抑制剂联合治疗,对照组单独应用DPP-4抑制剂治疗,随访16周,测定治疗前后血糖及生化指标,观察不良反应发生情况及治疗对C-RP的影响。结果治疗后,观察组FPG[(9.02±1.11)vs(7.14±1.41)mmol/L]、2hPG[(15.28±1.08)vs(9.85±1.59)mmol/L]、HbA_1c[(8.24±1.92)%vs(6.68±1.24)%]及C-RP[(8.82±1.71)vs(5.14±1.21)mg/L]水平降低;观察组HbA_1c的达标率高于对照组[76.67%(46/60)vs 63.33%(38/60)](P<0.05)。两组血糖指标和C-RP水平治疗前后差值(Δ值)比较,差异有统计学意义(P<0.05)。结论α糖苷酶抑制剂与DPP-4抑制剂联合应用与单独应用DPP-4抑制剂相比,治疗T2DM效果更好,且降低血清C-RP效果更佳。
Objective To investigate the efficacy and safety of α-glucosidase inhibitor and DPP-4 inhibitor in the treatment of T2DM. Methods 120 cases of T2DM were randomly divided into observation group and control group, each 60 cases. DPP-4 inhibitor was used in the observation group and DPP-4 inhibitor in the control group. After 16 weeks of follow-up, the blood glucose and biochemical indexes were measured before and after treatment. The incidence of adverse reactions, RP impact. Results After the treatment, the levels of FPG (9.02 ± 1.11 vs 7.14 ± 1.41 mmol / L), 2 hPG (15.28 ± 1.08) vs (9.85 ± 1.59) mmol / L and HbA 1c [(8.24 ± 1.92) (6.68 ± 1.24)% and C-RP [(8.82 ± 1.71) vs (5.14 ± 1.21) mg / L], respectively. The compliance rate of HbA 1c in observation group was higher than that in control group [76.67% (46/60) vs 63.33% (38/60)] (P <0.05). The differences of blood glucose and C-RP levels before and after treatment were statistically significant (P <0.05). Conclusions The combination of α-glucosidase inhibitor and DPP-4 inhibitor is better than that of DPP-4 inhibitor alone in treating T2DM, and the effect of reducing serum C-RP is better.